Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 3/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7362682 | 0.77 | HTR3A (1.00) | HTR3AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7363031 | 0.76 | HTR3A (0.98) | HTR3AALDH1A1 | |
| SCHEMBL7360573 | 0.76 | HTR3A (0.77) | HTR3AALDH1A1 | |
| SCHEMBL7386037 | 0.75 | HTR3A (0.59) | HTR3ACNR2 | |
| SCHEMBL1761622 | 0.73 | ADRA2A (0.57) | HTR3AADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL7360723 | 0.72 | HTR3A (0.58) | HTR3A | |
| SCHEMBL1761420 | 0.72 | ADRA2A (0.53) | HTR3AADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL7367774 | 0.71 | HTR3A (0.56) | HTR3A | |
| SCHEMBL4703891 | 0.70 | HTR3A (0.53) | HTR3AALDH1A1LMNAHPGD | |
| SCHEMBL1761719 | 0.70 | CHRNA7 (0.58) | HTR3AADRA2AADRA2BADRA2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118301-A1 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | claimed |
| EP-0530353-A1 | NEW IMIDAZOPYRIDINES AS SEROTONERGIC 5-HT 3? ANTAGONISTS | G.D. SEARLE & CO. (US) | 1993-03-10 | — | — | EP | claimed |
| EP-0504679-A1 | New imidazopyridines as serotonergic 5-HT3 antagonists | G.D. Searle & Co. (US) | 1992-09-23 | — | — | EP | claimed |
| WO-1992015593-A1 | NEW IMIDAZOPYRIDINES AS SEROTONERGIC 5-HT3 ANTAGONISTS | G.D. SEARLE & CO. (US) | 1992-09-17 | — | — | WO | claimed |
| US-20110118301-A1 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
| US-7897766-B2 | [3H]-(S,S)-2,2-dimethyl-5-(6-phenyl-pyridazin-3-yl)-5-aza-2-azonia-bicyclo[2.2.1]heptane, iodide; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, mild cognitive impairment, age-associated memory impairment | ABBOTT LABORATORIES (US) | 2011-03-01 | — | — | US | disclosed |
| EP-0530353-A1 | NEW IMIDAZOPYRIDINES AS SEROTONERGIC 5-HT 3? ANTAGONISTS | G.D. SEARLE & CO. (US) | 1993-03-10 | — | — | EP | disclosed |
| EP-0504679-A1 | New imidazopyridines as serotonergic 5-HT3 antagonists | G.D. Searle & Co. (US) | 1992-09-23 | — | — | EP | disclosed |
| WO-1992015593-A1 | NEW IMIDAZOPYRIDINES AS SEROTONERGIC 5-HT3 ANTAGONISTS | G.D. SEARLE & CO. (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118301-A1 | Amino-Aza-Adamantane Derivatives and Methods of Use | CHRNA7, CHRNA5, CHRNA1 | HTR3A 173/4885ADRA2A 61/4885ADRA2B 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.